Image source: Getty Images.
Shares in Dynavax Technologies Corp. (NASDAQ: DVAX) are surging by 26.6% at 3 p.m. EDT following reassurances by management that the Food and Drug Administration is still on track to issue an approval decision on its hepatitis B vaccine in mid-December.